Funding for this research was provided by:
(ZIA BC 010626, ZIA BC 011300)
Received: 23 December 2019
Accepted: 14 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: Ethics approval for the analyses reported here was provided by the Institutional Review Board (IRB) of the National Cancer Institute in Bethesda, MD, USA. All patients were enrolled on IRB-approved protocols and provided written informed consent to allow their tumor to be analyzed. Additionally, all patients who had germline testing were enrolled on a separate IRB-approved protocol and provided written informed consent for this analysis. No administrative permissions and/or licenses were required to access the clinical/personal patient data used in this study.
: Not applicable—no individually identifiable information included.
: The authors declare that they have no competing interests. None of the authors havefinancial or non-financial competing interests with this work.